A- A A+

Barriers to Prescribing Buprenorphine in the Emergency Department. 

Kim HS, Samuels EA. Overcoming 

JAMA Netw Open. 2020;3(5):e204996. doi:10.1001/jamanetworkopen.2020.4996

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2765700

USA. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63, Full Document.

This updated Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. (SAMHSA - Substance Abuse & Mental Health Services Administration, USA, Mai 2020)

https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP20-02-01-006.pdf

CLINICAL GUIDELINES FOR USE OF DEPOT BUPRENORPHINE (BUVIDAL®) IN THE TREATMENT OF OPIOID DEPENDENCE

This Clinical Guideline has been developed to inform decision-making by clinicians prescribing and/or patients being treated with Buvidal® long-acting injected buprenorphine preparations.

This guideline was funded by Camurus Ltd. The funding enabled SMMGP to provide clinical, managerial, editorial and administrative input. (SMMGP - Substance Misuse Management in General Practice, UK, April 2020)

https://www.smmgp-fdap.org.uk/clinical-guidelines-for-use-of-depot-buprenorphine-buvidal-in-the-treatment-of-opioid-dependence

EMA. Summary of opinion (post authorisation): Suboxone (buprenorphine / naloxone) sublingual film

On 30 April 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Suboxone. The marketing authorisation holder for this medicinal product is Indivior Europe Limited. 

The CHMP adopted a new pharmaceutical form (sublingual film) associated with four new strengths (2/0.5, 4/1, 8/2, and 16/4 mg) for either sublingual or buccal use. The new formulation adds additional safety features to prevent intravenous misuse. (EMA - European Medicines Agency, Amsterdam, 30 April 2020, EMA/CHMP/219873/2020, Committee for Medicinal Products for Human Use (CHMP) 

https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-suboxone-x-42_en.pdf

Two world first studies of depot buprenorphine completed

Two world first studies of depot buprenorphine have recently been completed. Both studies are great achievements at the forefront of international research efforts in this field and have salience as part of the response to COVID-19. (NDARC - National Drug and Alcohol Research Centre, Australien, April 2020)

https://ndarc.med.unsw.edu.au/two-world-first-studies-depot-buprenorphine-completed

Progress Report on EMBED: A Pragmatic Trial of User-Centered Clinical Decision Support to Implement EMergency Department-Initiated BuprenorphinE for Opioid Use Disorder.

Melnick ER, Nath B, Ahmed OM, Brandt C, Chartash D, Dziura JD, Hess EP, Holland WC, Hoppe JA, Jeffery MM, Katsovich L, Li F, Lu CC, Maciejewski K, Maleska M, Mao JA, Martel S, Michael S, Paek H, Patel MD, Platts-Mills TF, Rajeevan H, Ray JM, Skains RM, Soares WE 3rd, Deutsch A, Solad Y, D'Onofrio G.

J Psychiatr Brain Sci. 2020;5. pii: e200003. doi: 10.20900/jpbs.20200003. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164817/

Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis.

Andorn AC, Haight BR, Shinde S, Fudala PJ, Zhao Y, Heidbreder C, Learned SM, Fox NL, Nadipelli VR, Hassman D, Rutrick D.

J Clin Psychopharmacol. 2020 Apr 9. doi: 10.1097/JCP.0000000000001195.

Download -> PDF -> open access

https://journals.lww.com/psychopharmacology/Abstract/9000/Treating_Opioid_Use_Disorder_With_a_Monthly.98443.aspx

Implementation of emergency department-initiated buprenorphine for opioid use disorder in a rural southern state.

Bogan C, Jennings L, Haynes L, Barth K, Moreland A, Oros M, Goldsby S, Lane S, Funcell C, Brady K.

J Subst Abuse Treat. 2020 Mar;112S:73-78. doi: 10.1016/j.jsat.2020.02.007.

https://linkinghub.elsevier.com/retrieve/pii/S0740-5472(19)30592-6

Injectable buprenorphine for opioid use disorder: Effects on 1-year recovery outcomes

An extended release version of buprenorphine was recently approved by the FDA to treat opioid use disorder. Prior research has revealed the short-term benefits of buprenorphine on traditional treatment outcomes like substance use and acute harm (e.g., overdose). Building upon this literature, the current study assessed the longer-term effects of monthly buprenorphine injections on patient-centered outcomes like quality of life and health status, suggesting improved well-being up to 1 year of treatment. (Recovery Research Institute, USA, April 2020)

https://www.recoveryanswers.org/research-post/injectable-buprenorphine-1-year-outcomes/

Transitioning a patient from injectable opioid agonist therapy to sublingual buprenorphine/naloxone for the treatment of opioid use disorder using a microdosing approach.

Caulfield MDG, Brar R, Sutherland C, Nolan S.

BMJ Case Rep. 2020 Mar 25;13(3). pii: e233715. doi: 10.1136/bcr-2019-233715.

Abstract

https://casereports.bmj.com/content/13/3/e233715.long

Metabolic and Addiction Indices in Patients on Opioid Agonist Medication-Assisted Treatment: A Comparison of Buprenorphine and Methadone.

Elman I, Howard M, Borodovsky JT, Mysels D, Rott D, Borsook D, Albanese M.

Sci Rep. 2020 Mar 27;10(1):5617. doi: 10.1038/s41598-020-62556-0.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101411/

Emergency Department Clinicians' Attitudes Toward Opioid Use Disorder and Emergency Department-initiated Buprenorphine Treatment: A Mixed-Methods Study.

Im DD, Chary A, Condella AL, Vongsachang H, Carlson LC, Vogel L, Martin A, Kunzler N, Weiner SG, Samuels-Kalow M.

West J Emerg Med. 2020 Feb 21;21(2):261-271. doi: 10.5811/westjem.2019.11.44382.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081867/

Perioperative Management of a Patient Taking Suboxone® at the Time of Ambulatory Surgery.

Malan SH, Bailey CH, Khurmi N.

Case Rep Anesthesiol. 2020 Mar 9;2020:5628348. doi: 10.1155/2020/5628348. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085354/

Traditional Chinese Medicine-facilitated switch from methadone to buprenorphine-naloxone for treatment of heroin dependence: a case report.

Huang KY, Hsu CH, Yu KC, Yeh YH, Han KC, Wei HT.

J Tradit Chin Med. 2019 Apr;39(2):281-284.

PMID: 32186053

http://www.journaltcm.com/modules/Journal/contents/stories/192/18.pdf

Rapid Induction Therapy for Opioid-Use Disorder Using Buprenorphine Transdermal Patch: A Case Series.

Saal D, Lee F.

Perm J. 2020;24. doi: 10.7812/TPP/19.124. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089594/

Buprenorphin-Depot: Annäherung an das Äquivalenzprinzip in Haft - Besondere Eignung von Buvidal® zur Substitutionstherapie in der JVA 

Mannheim/Lund, 13.12.2019 – Die 4. Gefängnismedizintage am 5. und 6. Dezember 2019 in Frankfurt stießen auf reges Interesse bei Medizinern und Pflegekräften im Vollzug. Dem von der Camurus GmbH unterstützten Symposium „Das Depot – neue Wege in der Behandlung der Opioidabhängigkeit im Justizvollzug“ wohnten etwa 200 Besucher*innen bei. Mit der wachsenden Verfügbarkeit des Buprenorphin-Depots in Justizvollzugsanstalten kann eine deutliche Annäherung an das geforderte Äquivalenzprinzip erreicht werden, so ein Fazit der Referate und nachfolgenden Diskussion. (Camurus, Mannheim/Lund, 13.12.2019)

https://www.buvidal.de/wp-content/uploads/2020/02/202012_Bericht_Symposium_Naeher_am_Aequivalenzprinzip_mit-Buprenorphin-Depot.pdf

Rapid effect of a single-dose buprenorphine on reduction of opioid craving and suicidal ideation: A randomized, double blind, placebo-controlled study.

Ahmadi J, Sarani EM, Jahromi MS.

Ci Ji Yi Xue Za Zhi. 2019 Mar 14;32(1):58-64. doi: 10.4103/tcmj.tcmj_220_18. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015018/

Buprenorphine to reverse respiratory depression from methadone overdose in opioid-dependent patients: a prospective randomized trial.

Zamani N, Buckley NA, Hassanian-Moghaddam H.

Crit Care. 2020 Feb 7;24(1):44. doi: 10.1186/s13054-020-2740-y.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006192/

Sexual dysfunction in men on buprenorphine - naloxone-based substitution therapy.

Mattoo SK, Ghosh A, Subodh BN, Basu D, Satapathy A, Prasad S, Sharma MP.

Indian J Psychiatry. 2020 Jan-Feb;62(1):66-72. doi: 10.4103/psychiatry.IndianJPsychiatry_195_19. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964450/

Systematic benefit-risk assessment for buprenorphine implant: a semiquantitative method to support risk management.

Osborne V, Davies M, Roy D, Tescione F, Shakir SAW.

BMJ Evid Based Med. 2020 Feb 24. pii: bmjebm-2019-111295. doi: 10.1136/bmjebm-2019-111295.

https://ebm.bmj.com/content/early/2020/02/24/bmjebm-2019-111295.long

Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.

Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, Azocar F, Sanghavi DM.

JAMA Netw Open. 2020 Feb 5;3(2):e1920622. doi: 10.1001/jamanetworkopen.2019.20622.

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2760032

Perceptions of extended‐release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia.

Larance, B., Degenhardt, L., Grebely, J., Nielsen, S., Bruno, R., Dietze, P., Lancaster, K., Larney, S., Santo, T., Shanahan, M., Memedovic, S., Ali, R., and Farrell, M. ( 2020) 

Addiction, doi.org/10.1111/add.14941.

https://onlinelibrary.wiley.com/doi/full/10.1111/add.14941

Abuses of FDA Regulatory Procedures - The Case of Suboxone.

Haffajee RL, Frank RG.

N Engl J Med. 2020 Feb 6;382(6):496-498. doi: 10.1056/NEJMp1906680. 

The manufacturer of brand-name buprenorphine products exploited various FDA regulatory procedures to impede market entry of generic competitors and to maintain high prices. This case provides an example of the kinds of abuses that are common in prescription-drug markets.

Abstract

https://www.nejm.org/doi/full/10.1056/NEJMp1906680

Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: A long-term study.

Ling W, Nadipelli VR, Solem CT, Ronquest NA, Yeh YC, Learned SM, Mehra V, Heidbreder C.

J Subst Abuse Treat. 2020 Mar;110:1-8. doi: 10.1016/j.jsat.2019.11.004.

https://www.journalofsubstanceabusetreatment.com/article/S0740-5472(19)30168-0/fulltext

Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach.

Rozylo J, Mitchell K, Nikoo M, Durante SE, Barbic SP, Lin D, Mathias S, Azar P.

Addict Sci Clin Pract. 2020 Jan 15;15(1):2. doi: 10.1186/s13722-020-0177-x.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964069/

Early-Career and Graduating Physicians More Likely to Prescribe Buprenorphine.

Peterson LE, Morgan ZJ, Eden AR.

J Am Board Fam Med. 2020 Jan-Feb;33(1):7-8. doi: 10.3122/jabfm.2020.01.190230.

https://www.jabfm.org/content/33/1/7.long

Buprenorphine–cannabis interaction in patients undergoing opioid maintenance therapy

Vierke C, Marxen B, Boettcher M, Hiemke C, Havemann-Reinecke U.

Eur Arch Psychiatry Clin Neurosci (2020). doi.org/10.1007/s00406-019-01091-0

https://link.springer.com/article/10.1007%2Fs00406-019-01091-0

Recurrent Use of Implantable Buprenorphine.

Campbell MC.

Prim Care Companion CNS Disord. 2019 Dec 5;21(6). pii: 19l02434. doi: 10.4088/PCC.19l02434.

https://www.psychiatrist.com/pcc/article/pages/2019/v21n06/19l02434.aspx

A Retrospective Survey of Buprenorphine Substitute Treatment With Minimal Dosage in Heroin Use Disorder.

Shen W, Wang Q, Zhang J, Ping W, Zhang J, Ye W, Hu Q, Cerci D, Zhou W.

Front Psychiatry. 2019 Dec 4;10:888. doi: 10.3389/fpsyt.2019.00888. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904327/

Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation.

Ling W, Shoptaw S, Goodman-Meza D.

Subst Abuse Rehabil. 2019 Nov 29;10:69-78. doi: 10.2147/SAR.S155843. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889966/

  1. Willingness to take buprenorphine/naloxone among people who use opioids in Vancouver, Canada.
  2. Synthetic Urines in a Buprenorphine Clinic.
  3. Treatment of acute naloxone-precipitated opioid withdrawal with buprenorphine.
  4. Longitudinal analysis of HIV-risk behaviors of participants in a randomized trial of prison-initiated buprenorphine.
  5. New…and improved? The latest studies on injectable buprenorphine for opioid use disorder